Thus, we propose that the impairment of these pathways by STL001-mediated FOXM1 suppression may contribute to the increased vulnerability of FOXM1-deficient cancer cells universally to a broad range of chemotherapeutic drugs. The gene discussed is FOXM1; the disease is cancer.